Home > News > Pharmaceutical News

Venus bags Canadian patent for antibiotic Vancoplus

Posted on Sep 10, 06:09PM | IBNS

Venus Remedies Limited, (BSE Code-526953), a leading research based global pharmaceutical company, on Monday said it has secured its first patent from Canada for its novel antibiotic adjuvant entity Vancoplus.

The patent has been granted by the Canadian patent office and is valid up to May 2027.

The company is planning to launch the product in Canada in the next two years.

Commenting on this accomplishment, Dr. Manu Chaudhary, JMD, Director- Research, said, "We are really enthusiastic over the receival of this Canadian patent for Vancoplus, which will prove to be a fertile ground for the success of this product not just commercially but also in terms of catering to the constantly rising Methicillin Resistant Staphylococcus Aureus (MRSA) infection rates in Canada."

As per a research report published by Canadian Antimicrobial Resistance Alliance (CARA), the community acquired MRSA cases have increased significantly from 19.5pc in 2007 to 38.1pc in 2010.

Various studies and surveys conducted in Canada state that almost 40pc of the MRSA cases have arisen from the community with increase in MRSA infection amongst children and young adults who have no hospital contact or exposure.

There is a dramatic rise in the number of cases of Canadians getting infected by MRSA both in hospitals and within communities.

Discussing more about this patent, Chaudhary said, "At this time of need Vancoplus seems to be the only effective and safe option to curb the notorious MRSA strain.

"As the Canadian pharmaceutical market is the third fastest growing market globally, shows the great growth potential for R and D players in the industry to create better drugs to curb such diseases. With this patent we are hopeful of capturing a significant share in the Canadian Pharmaceutical market."

Dr. Mufti Suhail Sayeed, Sr. Vice President at Venus Medicine Research Centre (VMRC) stated that Vancoplus is an 'Antibiotic Adjuvant Entity' (AAE) constituting Ceftriaxone plus Vancomycin along with an adjuvant which restricts the production of toxin by MRSA pathogens and is highly effective in combating Methicillin Resistant Staphylococcus Aureus (MRSA) along with other advantages of reduced treatment time, cost and adverse effects.

The company has already been marketing Vancoplus successfully in India and few of the merging markets across the globe.

Venus Remedies' Baddi facility is already approved as per EU GMP for manufacturing of Vancoplus, which is in line with the Canadian Regulatory authorities to market the drug.

Vancoplus is growing with a CAGR of 50pc since past 3 years.

Apart from Canada, the patent for this product has already been granted from USA, South Africa, New Zealand, Ukraine and Australia.